Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Human CXCR4 Antibody, R&D Systems™

Mouse Monoclonal Antibody
Supplier: R&D Systems MAB170R100
This item is not returnable.
View return policy
Description
CXCR4 Monoclonal specifically detects CXCR4 in Human samples. It is validated for Flow Cytometry, Neutralization.Specifications
CXCR4 | |
Monoclonal | |
Unconjugated | |
Supplied as a solution in PBS. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS. with No Preservative | |
CD184, chemokine (C-X-C motif) receptor 4, chemokine (C-X-C motif), receptor 4 (fusin), C-X-C chemokine receptor type 4, CXC-R4, CXCR-4, D2S201E, D2S201ESDF-1 receptor, FB22, Fusin, HM89, HM89NPYRL, HSY3RR, LAP3, LAP-3, LCR1, LESTR, LESTRCD184 antigen, Leukocyte-derived seven transmembrane domain receptor, leukocyte-derived seven-transmembrane-domain receptor, lipopolysaccharide-associated protein 3, neuropeptide Y receptor Y3, NPY3R, NPY3RWHIM, NPYR, NPYRL, NPYY3R, pCXCR4, seven transmembrane helix receptor, seven-transmembrane-segment receptor, spleen, Stromal cell-derived factor 1 receptor, WHIMS | |
Mouse | |
Protein A or G purified from cell culture supernatant | |
RUO | |
7852 | |
Human | |
Purified |
Flow Cytometry, Neutralization | |
12G5R | |
Flow Cytometry 0.25 ug/10^6 cells, Neutralization 0.3-1.2 ug/mL | |
P61073 | |
CXCR4 | |
CP-MAC-infected SUP-T1 human T cell lymphoblastic lymphoma line Accession # P61073 | |
100 μg | |
Primary | |
Detects human CXCR4. | |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution. | |
IgG2a |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction